COMPANY
Carnation Therapeutics is a USA based pre-clinical stage cancer therapeutic company founded in 2022 with a mission to develop long-lasting immunotherapies for cancers using targeted delivery of Anti Sense Oligonucleotides (ASOs.)
CORE TEAM
Dr.Jarnail Singh PhD (Founder & CSO), USA (
[email protected])
With 25 years of combined experience in academia and industry, I have successfully led high-impact drug discovery programs before founding Carnation Therapeutics with a clear vision for success. My expertise spans cancer biology, mRNA transcription, immuno-oncology, and in vivo pharmacology. I have a proven track record of driving novel therapeutic candidates from discovery to clinical development while building and leading high-performing teams. My strategic approach, coupled with a deep understanding of both scientific and operational aspects, positions me to steer Carnation Therapeutics toward groundbreaking achievements and sustained success.
Dr.Senthil Saravanamuthu PhD (Co-Founder & CEO), USA (
[email protected])
As a seasoned, results-driven professional with 20 years of experience—8 years in cutting-edge scientific research and 12 years in sales and business development within the life sciences sector—I bring a unique and powerful skill set to Carnation Therapeutics. My ability to seamlessly blend scientific expertise with commercial acumen, combined with a creative approach and an exceptional work ethic, positions me as a critical driver for the company’s growth and success. My proven track record in both domains ensures that I can lead and innovate, propelling Carnation Therapeutics toward its strategic goals and industry leadership.
INDUSTRY
Category: Life Sciences Sub-Category: Drug Discovery/Pharmaceutical industry
CURRENT FUNDING STATUS: Currently Self-Funded by Founder & Co-founder.
ASK: Seeking funding of US$5M
USE OF FUNDS: With a strong pre-clinical pipeline and clear exit strategy we are looking to move our 1stdrug candidate to complete IND enabling studies & 2nd drug candidate beyond lead optimization stage between Oct 2024 and Sep 2026. Synthesis, Lead optimization, in vitro, in vivo studies, scale up and IND enabling studies.
PROBLEM: Existing Immunotherapies (checkpoint inhibitors) Are Ineffective For Majority (>80%) of The Cancer Patients
SOLUTION: Boost Anti-cancer Immune Response By Targeting A Broad-spectrum Immunosuppressive Gene ISK1 Achieving optimal response by targeting ISK1 requires inhibiting both its kinase dependent cellular functions as well as its scaffolding mediated role in Immune cell death
ISK1 AS A DRUG TARGET: In normal cells, ISK1 suppresses multiple types of immune cells leading to unchecked cancer progression. In addition, Tumor Microenvironment (TME) checkpoints such as PGE2, IDO, adenosine & TGF-beta activate ISK1 leading to enhanced immunosuppression. ISK1 knockdown activates multiple immune cell types to enhance tumor cell killing.
COMPETITION & DIFFERENTIATION: Unlike competitors developing ISK1 targeting small molecule inhibitor-based therapeutics, Carnation’s unique ASO mediated knockdown blocks both kinase-dependent and kinase independent roles of ISK1 leading to a best and first in class therapeutic for many different cancers.
VALUE PROPOSITION:
First in class opportunity using ASOs with potential multi billion dollars annual revenue
Current Market: >$40B
1st Tier Targeted Indications: Lung, Melanoma & Bladder cancer; Either alone or in combination with checkpoint inhibitors
2nd Tier Targeted Indications: Head & Neck, Colorectal, Stomach cancers; Combination with chemotherapy/checkpoint inhibitors
COMMERCIALIZATION PLAN:
Marketing on our own
• 5-6 years to commercialization
• Revenue $0.1- 0.5 Billion in year 1
• Revenue > $1 Billion annually from year 2
Strategic alliance with Pharma
• $50-100 Millions by year 3 or 4 upfront at signing
• Milestone payments at each step thereafter
• Annual royalty payments upon FDA approval (5-10% of sales)
EXIT STRATEGY
Venturing into Success: From IPOs to Acquisitions
• Option 1 - The rights of 1st drug sold to big pharma
• Option 2 - IPO launched
• Option 3 - Acquired by Big Pharma
PATENT STATUS Provisional Patent for ISK1 ASO filed to USPTO 02/22/2024
Please note ISK1 is a pseudonym we have used here to preserve confidentiality of our target gene. Real identity of our target gene can be revealed once a CDA is signed for further discussion from an interested investor.